Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.

Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, Yu DM

Cardiovascular diabetology5 Feb 2014Cited by 76 (Europe PMC)

PMID24498905PMCIDPMC3923001DOI10.1186/1475-2840-13-36PepBankPUB-24498905

Summary

Background and aimsLiraglutide treatment can improve glycemic control with a concomitant weight loss, but the underlying mechanism on weight loss is not completely understood. Cardiac natriuretic peptides (NPs) can resist body fat accumulation through increasing adipocytes lypolysis. In this study, we tested the hypothesis that liraglutide-induced weight loss was associated with increased plasma NPs concentrations.MethodsThirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks. Body composition, abdominal visceral adipose tissue areas (VAT) and subcutaneous adipose tissue areas (SAT) were assessed at pre- and post-treatment by dual-energy X-ray absorptiometry (DXA) scanning and abdominal computerized tomography (CT). Plasma atrial natriuretic peptides (ANP) and B-type ventricular natriuretic peptides (BNP) concentrations were tested by commercial ELISA Kit quantitatively.ResultsFollowing 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline. Concurrently, plasma ANP and BNP levels were significantly increased following 12-week liraglutide treatment. There were significant correlations between the reductions in body compositions and the increases in both plasma ANP and BNP levels.ConclusionsThere were significant correlations between increases in both plasma ANP and BNP levels and changes in liraglutide-induced body composition. Our data implied that increases in plasma NPs may add a novel dimension to explain how liraglutide induces weight loss.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 weeks of liraglutide significantly reduced body weight from baseline.
In plain wordsIn adults with type 2 diabetes, body weight fell after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890501
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 weeks of liraglutide significantly reduced waist circumference from baseline.
In plain wordsIn adults with type 2 diabetes, waist size fell after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890502
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 weeks of liraglutide significantly reduced total fat mass from baseline.
In plain wordsIn adults with type 2 diabetes, total body fat fell after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseTotal fat mass
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890503
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 weeks of liraglutide significantly reduced lean mass from baseline.
In plain wordsIn adults with type 2 diabetes, lean body mass fell after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseLean mass
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890504
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 weeks of liraglutide significantly reduced body fat percentage from baseline.
In plain wordsIn adults with type 2 diabetes, the share of body fat fell after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseFat percentage
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890505
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 weeks of liraglutide significantly reduced subcutaneous adipose tissue area from baseline.
In plain wordsIn adults with type 2 diabetes, fat under the skin of the abdomen fell after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous adipose tissue area
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890506
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 weeks of liraglutide significantly reduced visceral adipose tissue area from baseline.
In plain wordsIn adults with type 2 diabetes, deep abdominal fat fell after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue area
Study
n = 31
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Following 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890507
08HumanObservational studyMechanism
In adults with type 2 diabetes, plasma atrial natriuretic peptide levels rose significantly from baseline after 12 weeks of liraglutide.
In plain wordsIn adults with type 2 diabetes, blood levels of the heart hormone ANP rose after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
IncreasePlasma ANP level
Study
n = 31
Comparator
Baseline
Outcome group
Endogenous peptide levels · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Concurrently, plasma ANP and BNP levels were significantly increased following 12-week liraglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890508
09HumanObservational studyMechanism
In adults with type 2 diabetes, plasma B-type natriuretic peptide levels rose significantly from baseline after 12 weeks of liraglutide.
In plain wordsIn adults with type 2 diabetes, blood levels of the heart hormone BNP rose after 12 weeks of liraglutide treatment.
Peptide
Liraglutide
Outcome
IncreasePlasma BNP level
Study
n = 31
Comparator
Baseline
Outcome group
Endogenous peptide levels · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Concurrently, plasma ANP and BNP levels were significantly increased following 12-week liraglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890509
10HumanObservational studyMechanism
In adults with type 2 diabetes treated with liraglutide, reductions in body composition measures correlated significantly with increases in both plasma ANP and BNP.
In plain wordsIn adults with type 2 diabetes on liraglutide, bigger drops in body fat measures were linked to bigger rises in ANP and BNP.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of body composition reductions with ANP and BNP increases
Study
n = 31
Comparator
Baseline
Outcome group
Endogenous peptide levels · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
There were significant correlations between the reductions in body compositions and the increases in both plasma ANP and BNP levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks.
Show in the study text Report a problemFND-2449890510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.